P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.

Bibliographic Details
Main Authors:	Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Mackenzie Dobbins, Nitin Jain, Hussein Abbas, Steven Kornblau, Abhishek Maiti, Ivo Veletic, Taghi Manshouri, Sharon Bledsoe, Mary Ann Richie, Nakiuda Hall-Moore, Lingsha Zhou, Xuemei Wang, Hagop Kantarjian, Zeev Estrov, Srdan Verstovsek
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971000.57384.96

Similar Items

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
by: Taghi Manshouri, et al.
Published: (2022-05-01)

P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER
by: L. Masarova, et al.
Published: (2022-06-01)

Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
by: Taghi Manshouri, et al.
Published: (2019-01-01)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
by: Prithviraj Bose, et al.
Published: (2020-10-01)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
by: Friend R, et al.
Published: (2017-03-01)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
by: Kerry S. Campbell, et al.
Published: (2018-11-01)

P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS
by: J. Senapati, et al.
Published: (2022-06-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
by: Prithviraj Bose, et al.
Published: (2020-08-01)

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms
by: Tatiana Pazina, et al.
Published: (2017-09-01)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
by: Helen T. Chifotides, et al.
Published: (2022-01-01)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
by: Helen T. Chifotides, et al.
Published: (2023-06-01)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
by: Hans Michael Kvasnicka, et al.
Published: (2018-03-01)

Elotuzumab for the treatment of multiple myeloma
by: Yucai Wang, et al.
Published: (2016-07-01)

Negative regulation of humoral immunity due to interplay between the SLAMF1, SLAMF5, and SLAMF6 receptors
by: Ninghai eWang, et al.
Published: (2015-04-01)

Role and Mechanism of SLAMF7-SLAMF7 Signaling Pathway in Tumor Progression
by: WANG Yuanyuan, et al.
Published: (2020-04-01)

CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development.
by: Bonnie Huang, et al.
Published: (2016-01-01)

Elotuzumab as a novel anti-myeloma immunotherapy
by: Sabarinath Venniyil Radhakrishnan, et al.
Published: (2017-08-01)

Defining disease modification in myelofibrosis in the era of targeted therapy
by: Pemmaraju, N, et al.
Published: (2022)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
by: Liu YC, et al.
Published: (2014-06-01)

Responses to microbial challenges by SLAMF receptors
by: Boaz Job Van Driel, et al.
Published: (2016-01-01)

Migration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8.
by: Guoxing Wang, et al.
Published: (2015-01-01)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
by: Chen WC, et al.
Published: (2017-07-01)

Aristocracy, politics and power in Byzantium, 1025-1081
by: Nilsson, J
Published: (2017)

Laser surface modification of AISI 1025 steel
by: Nik Nadia Farhana, Nik Zulkifli
Published: (2013)

Basil II and the government of Empire (976-1025)
by: Holmes, C
Published: (1999)

CRISPR-Mediated Slamf1Δ/Δ Slamf5Δ/Δ Slamf6Δ/Δ Triple Gene Disruption Reveals NKT Cell Defects but Not T Follicular Helper Cell Defects.
by: Joyce K Hu, et al.
Published: (2016-01-01)

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
by: Mughal TI, et al.
Published: (2014-01-01)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
by: Lucia Masarova, et al.
Published: (2023-08-01)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
by: Francesca Palandri, et al.
Published: (2023-08-01)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

Direct synthesis of lactams related to UCS1025A
by: Ibbotson, L
Published: (2021)

SLAMF6 clustering is required to augment T cell activation.
by: Matthew A Dragovich, et al.
Published: (2019-01-01)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
by: Lucia Masarova, et al.
Published: (2023-08-01)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
by: A. Vannucchi, et al.
Published: (2022-06-01)

Abstract 10.25–11.15 Session 7- Regeneration
Published: (2018-06-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
by: Seunghee Kim-Schulze, et al.
Published: (2024-04-01)

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
by: I. Vaxman, et al.
Published: (2022-06-01)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liping Liu, et al.
Published: (2016-07-01)